Hologic has announced the completion of Somatex Medical Technologies GmbH, a biopsy site markers and localization technologies provider, for approximately $64 million. Hologic (HOLX) said that the Somatex deal will help the company expand its growing biopsy portfolio. The deal is in-line with the medical technology company's strategy to offer “innovative solutions across the continuum of breast health care.” The acquisition is expected to be slightly accretive to Hologic's adjusted earnings at the beginning of the current fiscal year.